Ribavirin prophylaxis enabled successful autologous transplantation of hepatitis E-contaminated stem cells (2,950,000 IU/mL), with no HEV reactivation at >12 months post-transplant.
Does ribavirin prophylaxis prevent HEV re-activation in a patient receiving a hepatitis E contaminated stem cell product?
Ribavirin prophylaxis may be a successful management strategy when using hepatitis E contaminated stem cell products in autologous stem cell transplantation.
Absolute Event Rate: 0% vs 0%
This is the first case of the prospective use of a CD34-contaminated hepatitis E stem cell product with a high viral load (2,950,000 IU/mL) in an autologous stem cell transplant setting. We describe the successful prophylaxis with ribavirin. This case provides a practical management strategy for a HSCT, particularly in the allogeneic setting, where time-critical donor CD34 products are required where acute HEV infection is detected. Our patient remains alive at >12 months post-transplant with no evidence of HEV re-activation.
Sadler et al. (Thu,) reported a other. Ribavirin prophylaxis enabled successful autologous transplantation of hepatitis E-contaminated stem cells (2,950,000 IU/mL), with no HEV reactivation at >12 months post-transplant.